RE:RE:RE:Mugsthemagicbox wrote: The interview was recorded, so itll be posted on Radius Research's youtube channel either later today or tomorrow. https://www.youtube.com/c/radiusresearch
the main takeaway as far as SP movement is concerend wont happen till mid next year when they expect to enter ph2 of this acute pain indication. He acknowledge that many investors are waiting for more concrete data and plans before re-entering
from a drug deveolpment perspective, it seems that the current hypothesis for the liver enzyme elevation is that the exogenous H2S from H2S moiety is inhibiting endogenous H2S. So the body isnt able to generate its own H2S as before. Consequently contributing to liver enzyme issue.
While this isnt an issue at all for the acute indication (which is a 14 day regimen) its a problem for the chronic indication.
Right - which is exactly why I'd bet (worst case) on a higher dosing OTENA to start a chronic regimen, followed by Naproxen until you get to a point where you need to repeat OTENA ... over and over, keeping enough painkiller in the body - just enough H2S in the body - and the liver unconfused. Anyway ... that sticks in my head.
Anyway ... from the conference, these are the things that stick with me ...
1. Seems like we are in the final phase of selling Citagenix - hoping they just needed these quarterly financials to complete the formal part of the deal. With the changes made to the financials, they are absolutely serious about a sale. IMO
2. At the level of exposure exected for Acute, not one person out of >600 has had issues - if I understood that correctly, wouldn't that mean they have a really good idea where the Acute dosing will be?
3. "No need to go to market for cash for a long time, if at all."